2: Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. 2012
Add to clipboard

3: Insulin-induced mTOR activity exhibits anti-hepatitis C virus activity. 2012
Add to clipboard

4: Leucine and arginine regulate trophoblast motility through mTOR-dependent and independent pathways in the preimplantation mouse embryo. 2012
Add to clipboard

5: mTOR-rictor is the Ser(473) kinase for AKT1 in mouse one-cell stage embryos. 2012
Add to clipboard

6: The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. 2012
Add to clipboard

7: Current development of the second generation ofmTOR inhibitors as anticancer agents. 2012
Add to clipboard

8: CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. 2012
Add to clipboard

9: Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). 2012
Add to clipboard

10: Biochemical and pharmacological inhibition ofmTOR by rapamycin and an ATP-competitivemTOR inhibitor. 2012
Add to clipboard

11: mTOR activity under hypoxia. 2012
Add to clipboard

12: Isolation of the mTOR complexes by affinity purification. 2012
Add to clipboard

13: Detection of cytoplasmic and nuclear functions of mTOR by fractionation. 2012
Add to clipboard

14: Evaluation of mTOR-regulated mRNA translation. 2012
Add to clipboard

15: Quantitative visualization of autophagy induction by mTOR inhibitors. 2012
Add to clipboard

16: Expanding human T regulatory cells with themTOR-inhibitor rapamycin. 2012
Add to clipboard

17: Utilizing a retroviral RNAi system to investigate in vivo mTOR functions in T cells. 2012
Add to clipboard

18: Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes. 2012
Add to clipboard

19: Evaluating the therapeutic potential of mTORinhibitors using mouse genetics. 2012
Add to clipboard

20: Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. 2012
Add to clipboard

21: Assessing the function of mTOR in human embryonic stem cells. 2012
Add to clipboard

22: Development of ATP-competitive mTORinhibitors. 2012
Add to clipboard

23: mTOR inhibitor-associated proteinuria in kidney transplant recipients. 2012
Add to clipboard

24: Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. 2012
Add to clipboard

25: The role of mTOR signaling in Alzheimer disease. 2012
Add to clipboard

26: mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma. 2012
Add to clipboard

27: Kinome-wide selectivity profiling of ATP-competitive mTOR (mammalian target ofrapamycin) inhibitors and characterization of their binding kinetics. 2012
Add to clipboard

28: Analysis of the pharmacodynamic activity of themTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. 2012
Add to clipboard

29: Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat. 2012
Add to clipboard

30: Immunohistochemical analysis of the mTORpathway in intrahepatic cholangiocarcinoma. 2012
Add to clipboard

31: miR-376b controls starvation and mTORinhibition-related autophagy by targeting ATG4C and BECN1. 2012
Add to clipboard

32: A Novel Application of Topical RapamycinFormulation, an Inhibitor of mTOR, for Patients With Hypomelanotic Macules in Tuberous Sclerosis Complex. 2012
Add to clipboard

33: Systemic Bisperoxovanadium Activates Akt/mTOR, Reduces Autophagy, and Enhances Recovery following Cervical Spinal Cord Injury. 2012
Add to clipboard

34: HIV-1 Promotes Renal Tubular Epithelial Cell Protein Synthesis: Role of mTOR Pathway. 2012
Add to clipboard

35: Roles of the mammalian target of rapamycin,mTOR, in controlling ribosome biogenesis and protein synthesis. 2012
Add to clipboard

36: mTOR inhibitors in cancer therapy. 2012
Add to clipboard

37: mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. 2012
Add to clipboard

38: The progesterone-induced enhancement of object recognition memory consolidation involves activation of the extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR) pathways in the dorsal hippocampus. 2012
Add to clipboard

39: Drug Interaction Between Cyclosporine andmTOR Inhibitors in Experimental Model of Chronic Cyclosporine Nephrotoxicity and Pancreatic Islet Dysfunction. 2012
Add to clipboard

40: Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with Fragile X syndrome. 2012
Add to clipboard

41: AKT/mTOR activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. 2012
Add to clipboard

42: PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. 2012
Add to clipboard

43: Role of mTOR in neuroprotection and axon regeneration after inflammatory stimulation. 2012
Add to clipboard

44: Mycobacterial induction of autophagy varies by species and occurs independently of mTORinhibition. 2012
Add to clipboard

45: Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes. 2012
Add to clipboard

46: mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma. 2012
Add to clipboard

47: Sustained antitumor activity by co-targetingmTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. 2012
Add to clipboard

48: Deregulated mTOR-mediated translation in intellectual disability. 2012
Add to clipboard

49: Hypothalamic mTOR pathway mediates thyroid hormone-induced hyperphagia in hyperthyroidism. 2012
Add to clipboard

50: [(11)C]GSK2126458 and [(18)F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. 2012
Add to clipboard

51: Isoleucine and Leucine Independently RegulatemTOR Signaling and Protein Synthesis in MAC-T Cells and Bovine Mammary Tissue Slices. 2012
Add to clipboard

52: The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils. 2012
Add to clipboard

53: Arrest of Myelination and Reduced Axon Growth When Schwann Cells Lack mTOR. 2012
Add to clipboard

54: Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor ofmTOR. 2012
Add to clipboard

55: Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells. 2012
Add to clipboard

56: Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTORcomplex 2 (mTORC2). 2012
Add to clipboard

57: mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. 2012
Add to clipboard

58: Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. 2012
Add to clipboard

59: HER2+ Breast Cancer Therapy: By CPP-ZFN Mediated Targeting of mTOR? 2012
Add to clipboard

60: Inhibition of chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. 2012
Add to clipboard

61: Akt Inhibitors MK-2206 and Nelfinavir overcomemTOR inhibitor resistance in DLBCL. 2012
Add to clipboard

62: Dose-Dependent Effects of Sirolimus on mTORSignaling and Polycystic Kidney Disease. 2012
Add to clipboard

63: Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. 2012
Add to clipboard

64: Critical role of arachidonic acid-activated mTORsignaling in breast carcinogenesis and angiogenesis. 2012
Add to clipboard

65: Modulation of mTOR effector phosphoproteins in blood basophils from allergic patients. 2012
Add to clipboard

66: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. 2012
Add to clipboard

67: Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemia. 2012
Add to clipboard

68: Role of PRAS40 in Akt and mTOR signaling in health and disease. 2012
Add to clipboard

69: Intestinal cell kinase (ICK) promotes activation ofmTOR complex 1 (mTORC1) through phosphorylation of Raptor Thr-908. 2012
Add to clipboard

70: Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. 2012
Add to clipboard

71: The translational landscape of mTOR signalling steers cancer initiation and metastasis. 2012
Add to clipboard

72: Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway. 2012
Add to clipboard

73: Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTORpathway and induction of autophagy. 2012
Add to clipboard

74: Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. 2012
Add to clipboard

75: Biologic rationale and clinical activity of mTORinhibitors in gynecological cancer. 2012
Add to clipboard

76: Cross talk between estradiol and mTOR kinase in the regulation of ovarian granulosa proliferation. 2012
Add to clipboard

77: CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. 2012
Add to clipboard

78: Non-small cell lung carcinoma therapy usingmTOR-siRNA. 2012
Add to clipboard

79: Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. 2012
Add to clipboard

80: Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells. 2012
Add to clipboard

81: mTOR is required for asymmetric division through small GTPases in mouse oocytes. 2012
Add to clipboard

82: The mTOR Signalling Pathway in Human Cancer. 2012
Add to clipboard

83: mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas. 2012
Add to clipboard

84: mTOR kinase inhibitors as a treatment strategy in hematological malignancies. 2012
Add to clipboard

85: The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. 2012
Add to clipboard

86: PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTORinhibitors. 2012
Add to clipboard

87: Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types. 2012
Add to clipboard

88: Prolactin and epidermal growth factor stimulate adipophilin synthesis in HC11 mouse mammary epithelial cells via the PI3-kinase/Akt/mTORpathway. 2012
Add to clipboard

89: Delayed mTOR inhibition with low dose of everolimus reduces TGFbeta expression, attenuates proteinuria and renal damage in the renal mass reduction model. 2012
Add to clipboard

90: Inhibition of MTOR disrupts autophagic flux in podocytes. 2012
Add to clipboard

91: Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. 2012
Add to clipboard

92: PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter. 2012
Add to clipboard

93: InTERTesting association between telomerase,mTOR and phytochemicals. 2012
Add to clipboard

94: A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation. 2012
Add to clipboard

95: Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. 2012
Add to clipboard

96: Major involvement of mTOR in the PPARgamma-induced stimulation of adipose tissue lipid uptake and fat accretion. 2012
Add to clipboard

97: Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. 2012
Add to clipboard

98: Shear stress induces cell apoptosis via a c-Src-phospholipase D-mTOR signaling pathway in cultured podocytes. 2012
Add to clipboard

99: Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. 2012
Add to clipboard

100: Targeting mTOR Pathways in Human Malignancies. 2012
Add to clipboard

101: Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. 2012
Add to clipboard

102: Regulation of the glutamate transporter EAAT3 by mammalian target of rapamycin mTOR. 2012
Add to clipboard

103: The role and regulation of mTOR in T-lymphocyte function. 2012
Add to clipboard

104: A Role of the Mammalian Target of Rapamycin(mTOR) in Glutamate-Induced Down-regulation of Tuberous Sclerosis Complex Proteins 2 (TSC2). 2012
Add to clipboard

105: Osmotic Stress Regulates Mammalian Target of Rapamycin (mTOR) Complex 1 via c-Jun N-terminal Kinase (JNK)-mediated Raptor Protein Phosphorylation. 2012
Add to clipboard

106: An overview of the mTOR pathway as a target in cancer therapy. 2012
Add to clipboard

107: mTOR-dependent modulation of gastric nesfatin-1/NUCB2. 2012
Add to clipboard

108: Cooperative action of JNK and AKT/mTOR in 1-methyl-4-phenylpyridinium-induced autophagy of neuronal PC12 cells. 2012
Add to clipboard

109: Regulation and function of mTOR signalling in T cell fate decisions. 2012
Add to clipboard

110: mTOR signaling pathway and mTOR inhibitors in cancer therapy. 2012
Add to clipboard

111: The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas. 2012
Add to clipboard

112: Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. 2012
Add to clipboard

113: Regulation of the mTOR signaling network in hibernating thirteen-lined ground squirrels. 2012
Add to clipboard

114: mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. 2012
Add to clipboard

115: Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy. 2012
Add to clipboard

116: Ubiquitin Specific Peptidase 9, X-linked (USP9X) Modulates the Activity of Mammalian Target of Rapamycin (mTOR). 2012
Add to clipboard

117: Inflammation-Driven Reprogramming of CD4(+)Foxp3(+) Regulatory T Cells into Pathogenic Th1/Th17 T Effectors Is Abrogated by mTORInhibition in vivo. 2012
Add to clipboard

118: N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. 2012
Add to clipboard

119: mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma. 2012
Add to clipboard

120: Simultaneous targeting of EGFR and mTORinhibits the growth of colorectal carcinoma cells. 2012
Add to clipboard

121: mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. 2012
Add to clipboard

122: The PP242 Mammalian Target of Rapamycin(mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance. 2012
Add to clipboard

123: The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. 2012
Add to clipboard

124: Cardiac mTOR protects the heart against ischemia-reperfusion injury. 2012
Add to clipboard

125: Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. 2012
Add to clipboard

126: Suppression of proinvasive RGS4 by mTORinhibition optimizes glioma treatment. 2012
Add to clipboard

127: The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. 2012
Add to clipboard

128: AKT/mTOR as Novel Targets of Polyphenol Piceatannol Possibly Contributing to Inhibition of Proliferation of Cultured Prostate Cancer Cells. 2012
Add to clipboard

129: Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. 2012
Add to clipboard

130: Finding a better drug for epilepsy: The mTORpathway as an antiepileptogenic target. 2012
Add to clipboard

131: Reduction of insulin signalling pathway IRS-1/IRS-2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid-treated rats. 2012
Add to clipboard

132: The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis. 2012
Add to clipboard

133: Metformin and the mTOR Inhibitor Everolimus (RAD001) Sensitize Breast Cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro. 2012
Add to clipboard

134: Tumor necrosis factor-alpha (TNF-alpha)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTORcomplex 1 (mTORC1), but not mTOR complex 2(mTORC2) signaling. 2012
Add to clipboard

135: Neuregulin Promotes Incomplete Autophagy of Prostate Cancer Cells That Is Independent of mTORPathway Inhibition. 2012
Add to clipboard

136: The mTOR pathway is activated in glial cells in mesial temporal sclerosis. 2012
Add to clipboard

137: Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders. 2012
Add to clipboard

138: Evidence of Ambiguous Differentiation andmTOR Pathway Dysregulation in Subependymal Giant Cell Astrocytoma. 2012
Add to clipboard

139: Leucine stimulates insulin secretion via down-regulation of surface expression of adrenergic alpha 2A receptor through the mTOR pathway and its implication in new-onset diabetes in renal transplantation. 2012
Add to clipboard

140: Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer. 2012
Add to clipboard

141: Leucine induces myofibrillar protein accretion in cultured skeletal muscle through mTOR dependent and -independent control of myosin heavy chain mRNA levels. 2012
Add to clipboard

142: Alterations of the p53 and PIK3CA/AKT/mTORpathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics. 2012
Add to clipboard

143: Akt (protein kinase B) isoform phosphorylation and signaling downstream of mTOR (mammalian target of rapamycin) in denervated atrophic and hypertrophic mouse skeletal muscle. 2012
Add to clipboard

144: Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTORInhibitor, RAD001, in Endometrial Carcinomas. 2012
Add to clipboard

145: Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. 2012
Add to clipboard

146: Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTORsignaling. 2012
Add to clipboard

147: Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling. 2012
Add to clipboard

148: Rapamycin Inhibits the mTOR/p70S6K Pathway and Attenuates Cardiac Fibrosis in Adriamycin-induced Dilated Cardiomyopathy. 2012
Add to clipboard

149: Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation. 2012
Add to clipboard

150: Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. 2012
Add to clipboard

151: Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. 2012
Add to clipboard

152: The mTOR-inhibitor Rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. 2012
Add to clipboard

153: Nuclear factor of activated T-cells (NFAT) c3 inhibition of mTOR signaling through induction of REDD1 in human intestinal cells. 2012
Add to clipboard

154: Caveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment: Chemoprevention with Rapamycin, an mTOR Inhibitor and Anti-Aging Drug. 2012
Add to clipboard

155: Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. 2012
Add to clipboard

156: Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regulating the Akt/mTOR and Akt/GSK-3beta signaling pathways. 2012
Add to clipboard

157: Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma. 2012
Add to clipboard

158: Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. 2012
Add to clipboard

159: Lymphedema of the Breast as a Symptom of Internal Diseases or Side Effect of mTorInhibitors. 2012
Add to clipboard

160: Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. 2012
Add to clipboard

161: L-Leucine improves anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q)MDS by activating the mTORpathway. 2012
Add to clipboard

162: Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways. 2012
Add to clipboard

163: Targeting the mTOR-DEPTOR Pathway by CRL E3 Ubiquitin Ligases: Therapeutic Application. 2012
Add to clipboard

164: Chronic inhibition of mTOR by rapamycinmodulates cognitive and non-cognitive components of behavior throughout lifespan in mice. 2012
Add to clipboard

165: [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus]. 2012
Add to clipboard

166: Mapping the Spatio-Temporal Pattern of the Mammalian Target of Rapamycin (mTOR) Activation in Temporal Lobe Epilepsy. 2012
Add to clipboard

167: mTOR Is Essential for the Proteotoxic Stress Response, HSF1 Activation and Heat Shock Protein Synthesis. 2012
Add to clipboard

168: Identification of Akt-Independent Regulation of Hepatic Lipogenesis by Mammalian Target ofRapamycin (mTOR) Complex 2. 2012
Add to clipboard

169: Glucocorticoids Modulate the mTOR Pathway in the Hippocampus: Differential Effects Depending on Stress History. 2012
Add to clipboard

170: Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. 2012
Add to clipboard

171: Resistance to the mTOR-inhibitor RAD001 elevates integrin alpha2- and beta1-triggered motility, migration and invasion of prostate cancer cells. 2012
Add to clipboard

172: Response to Comment on"A Dynamic Network Model of mTOR Signaling Reveals TSC-IndependentmTORC2 Regulation": Building a Model of themTOR Signaling Network with a Potentially Faulty Tool. 2012
Add to clipboard

173: Immunohistochemical Analysis of the Akt/mTOR/4E-BP1 Signalling Pathway in Canine Haemangiomas and Haemangiosarcomas. 2012
Add to clipboard

174: Altered LKB1/AMPK/TSC1/TSC2/mTORsignaling causes disruption of Sertoli cell polarity and spermatogenesis. 2012
Add to clipboard

175: Identification of mammalian target ofrapamycin (mTOR) as a direct target of fenretinib both in vitro and in vivo. 2012
Add to clipboard

176: Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype. 2012
Add to clipboard

177: Advancing age is associated with gene expression changes resembling mTOR inhibition: Evidence from two human populations. 2012
Add to clipboard

178: Glutamate transporter-dependent mTORphosphorylation in Muller glia cells. 2012
Add to clipboard

179: Dual targeting of mTOR and Aurora-A kinase for the treatment of uterine leiomyosarcoma. 2012
Add to clipboard

180: The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis. 2012
Add to clipboard

181: Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment. 2012
Add to clipboard

182: Constitutive activation of the mTOR signaling pathway within the normal glomerulus. 2012
Add to clipboard

183: EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. 2012
Add to clipboard

184: Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. 2012
Add to clipboard

185: Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer. 2012
Add to clipboard

186: Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold. 2012
Add to clipboard

187: IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. 2012
Add to clipboard

188: PI3K/mTOR Signaling Pathways in Medulloblastoma. 2012
Add to clipboard

189: Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. 2012
Add to clipboard

190: N-Carbamylglutamate Enhances Pregnancy Outcome in Rats through Activation of the PI3K/PKB/mTOR Signaling Pathway. 2012
Add to clipboard

191: Hepatitis B Virus X Protein Upregulates mTORSignaling through IKKbeta to Increase Cell Proliferation and VEGF Production in Hepatocellular Carcinoma. 2012
Add to clipboard

192: Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically-defined head and neck squamous cell carcinoma mouse model. 2012
Add to clipboard

193: Pharmacological targeting of mammalian target of rapamycin (mTOR) inhibits ovarian granulosa cell tumor growth. 2012
Add to clipboard

194: New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs). 2011
Add to clipboard

195: The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated byrapamycin. 2011
Add to clipboard

196: Activation of mTOR and RhoA is a major